MESO Q4 2025 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+458.6% YoY

Gross Profit

-$16M-231.1% margin

Operating Income

-$34M-489.5% margin

Net Income

-$27M-386.0% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$785M

Total Liabilities

$187M

Stockholders' Equity

$597M

Cash & Equivalents

$161M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$1M	+458.6%
Gross Profit	-$16M	-$10M	-69.4%
Operating Income	-$34M	-$22M	-56.2%
Net Income	-$27M	-$28M	+2.2%